As Americans prepare to mark another 4/20 celebration, the momentum behind nationwide marijuana legalization appears to have stalled despite persistent public support. Polls consistently show a majority of Americans favor legalizing cannabis for both medical and recreational employ, yet recent ballot initiatives have failed and federal reform efforts face political headwinds. This disconnect between public opinion and policy outcomes highlights the complex interplay of state politics, industry dynamics, and evolving health research shaping the future of cannabis legalization in the United States.
The stalled progress comes after a decade of rapid expansion. Since Colorado and Washington first legalized recreational marijuana in 2012, 24 states and Washington, D.C. Have approved adult-use cannabis programs, according to the National Conference of State Legislatures. Medical cannabis is now legal in 38 states and three territories, creating a patchwork of regulations that varies widely in terms of access, taxation, and social equity provisions. Despite this state-level success, cannabis remains classified as a Schedule I controlled substance under federal law, creating ongoing conflicts between state and federal authorities.
Recent developments have further complicated the landscape. In 2022, President Biden pardoned thousands of individuals convicted of federal simple possession of marijuana and initiated a review of cannabis’s scheduling under the Controlled Substances Act. The Department of Health and Human Services subsequently recommended rescheduling marijuana to Schedule III, a move that would acknowledge its medical potential whereas maintaining federal restrictions. As of April 2024, the Drug Enforcement Administration was still reviewing this recommendation, with no final rule issued.
Political divisions sluggish reform efforts
One of the primary obstacles to nationwide legalization is the stark partisan divide on cannabis policy. While Democratic and independent voters overwhelmingly support legalization, Republican voters remain significantly more divided. A March 2024 Pew Research Center survey found that 72% of Democrats and Democratic-leaning independents favor legalizing marijuana for both medical and recreational use, compared to only 45% of Republicans and Republican-leaning independents.
This political split is reflected in state governments. Of the 26 states that have not legalized recreational marijuana, 20 have Republican-controlled state governments, according to data from the National Conference of State Legislatures. Another four states have Republican-controlled legislatures with split or Democratic governorships. Only Hawaii has a Democratic-controlled government that has not yet legalized recreational cannabis, though medical use has been permitted there since 2000.
The 2024 election cycle underscored these challenges. Ballot measures to legalize recreational marijuana failed in Florida, North Dakota, and South Dakota, marking the poorest showing for cannabis legalization initiatives in recent years. In Florida, despite 60% voter support for Amendment 3, the measure failed to reach the 60% supermajority required for constitutional amendments. Nebraska voters approved medical marijuana initiatives, but implementation has been delayed by legislative disputes and legal challenges.
Federal reform faces procedural hurdles
Efforts to reform federal cannabis policy have encountered procedural and political obstacles. The Biden administration’s review of marijuana’s scheduling under the Controlled Substances Act remains incomplete, with the DEA missing multiple self-imposed deadlines for issuing a final rule. As of March 2024, the agency had not published its decision in the Federal Register, leaving the rescheduling process in limbo.
Legislative efforts in Congress have also stalled. The Cannabis Administration and Opportunity Act, which would deschedule marijuana, expunge federal cannabis-related convictions, and establish a federal regulatory framework, has lacked sufficient Republican support to advance. Similarly, the SAFE Banking Act, designed to provide cannabis businesses access to banking services, has passed the House multiple times but repeatedly failed to gain traction in the Senate due to concerns about broader drug policy implications.
These delays have real-world consequences. Cannabis businesses continue to operate largely on a cash-only basis due to federal banking restrictions, creating security risks and complicating tax compliance. The Internal Revenue Service’s enforcement of Section 280E of the tax code, which prohibits deductions for businesses trafficking in Schedule I or II substances, results in effective tax rates that can exceed 70% for cannabis companies, according to industry analysts.
Health research fuels debate
Evolving scientific understanding of cannabis’s health effects is influencing both public opinion and policy debates. While early legalization efforts emphasized cannabis’s relative safety compared to alcohol and tobacco, recent research has highlighted potential risks associated with regular use, particularly among adolescents.
A 2023 study published in JAMA Psychiatry found that frequent cannabis use during adolescence was associated with an increased risk of developing psychotic disorders, with the strongest links observed in individuals who began using before age 18. The study’s authors noted that while correlation does not equal causation, the findings warrant caution regarding youth access to high-potency cannabis products.
Research into cannabis’s medical efficacy has also produced mixed results. A 2024 review by the Journal of the American Medical Association concluded that while cannabis shows promise for treating chronic pain in adults and reducing chemotherapy-induced nausea, evidence supporting its use for conditions like anxiety, depression, and insomnia remains limited. The review emphasized the need for more rigorous, placebo-controlled studies to establish clear therapeutic guidelines.
These findings have prompted some previously supportive voices to reassess their positions. In February 2024, The Modern York Times editorial board published a piece acknowledging that “the loosening of marijuana policies … has led to worse outcomes than many Americans expected,” particularly regarding youth mental health and public consumption. The editorial called for stricter regulation of legal markets rather than a return to prohibition.
Industry growth creates internal tensions
The rapid commercialization of the cannabis industry has exposed long-standing tensions between business interests and social justice advocates. As legal markets have expanded, concerns have grown about market consolidation and whether early promises of equity and inclusion are being fulfilled.
In 2022, the organization True Social Equity in Cannabis filed a lawsuit alleging anticompetitive practices by three major Illinois cannabis companies, which activists dubbed the “Chicago cartel” in court documents. Whereas the case was voluntarily dismissed, it highlighted fears that legalization could create new forms of corporate dominance that marginalize small businesses and communities disproportionately affected by past drug enforcement.
These concerns have been amplified by political figures in states resisting legalization. Florida Governor Ron DeSantis repeatedly warned voters that approving recreational marijuana would create a “weed cartel” dominated by large, out-of-state corporations during his successful campaign against Amendment 3 in 2024. Similar rhetoric has emerged in other states where legalization measures have faced opposition.
Industry data supports concerns about market concentration. According to Whitney Economics, the top 10 cannabis operators in the United States controlled approximately 38% of total retail sales in 2023, up from 29% in 2021. This trend toward consolidation raises questions about whether legal markets will deliver on their promise of broad-based economic opportunity.
Hemp industry faces regulatory upheaval
Related to the marijuana debate, the hemp industry is undergoing significant regulatory changes that could reshape the broader cannabis landscape. The 2018 Farm Bill legalized hemp production, defining it as cannabis plants containing less than 0.3% delta-9 THC by dry weight. However, innovation in hemp-derived products has led to the proliferation of items containing other forms of THC, such as delta-8 and delta-10, which exist in a legal gray area.
In response, Congress included provisions in the 2025 Tax Cuts and Jobs Act that would effectively ban many intoxicating hemp products by closing loopholes that allowed for the sale of synthetically derived cannabinoids. When these provisions take effect, expected in late 2024 or early 2025, products like THC-infused beverages and gummies currently sold in many states will become illegal under federal law.
States are already responding to these changes. Tennessee and Iowa have passed legislation restricting the sale of intoxicating hemp products, with Iowa’s law specifically targeting delta-8 THC and similar compounds. In Des Moines, Iowa, a dispensary that once employed 30 people closed in March 2024 after new state regulations limited its product offerings, illustrating the real-world impact of these regulatory shifts.
These developments highlight the interconnected nature of cannabis policy reform. Changes to hemp regulations could influence public perception of cannabis more broadly and affect the political calculus surrounding marijuana legalization efforts.
Public support remains strong but uneven
Despite policy setbacks, public opinion polls consistently show durable majority support for cannabis legalization. A Gallup survey conducted in November 2023 found that 70% of Americans favor legalizing marijuana, the highest level recorded since the poll began tracking the issue in 1969. Support cuts across demographic lines, though variations exist by age, political affiliation, and region.
Younger Americans show the strongest backing, with 82% of adults aged 18 to 34 favoring legalization, compared to 58% of those aged 55, and older. Regional differences are also pronounced, with Western states showing the highest support (78%) and Southern states the lowest (62%), according to the same Gallup data.
This enduring public support suggests that a return to nationwide prohibition is unlikely, even as legalization efforts face short-term obstacles. However, the gap between public opinion and policy outcomes reveals the complexity of translating broad societal attitudes into legislative action, particularly in a federal system where states retain significant autonomy over drug policy.
What happens next?
The future of marijuana legalization will likely depend on developments in several key areas. At the federal level, the DEA’s decision on rescheduling remains pending, with no clear timeline for completion. Congressional action on banking reform or broader descheduling legislation appears unlikely in the near term given current political dynamics.
At the state level, advocates are shifting strategies. Rather than relying solely on ballot initiatives, some groups are focusing on legislative campaigns in states with more favorable political environments. Others are emphasizing public education campaigns to address health concerns and build broader coalitions that include law enforcement officials, medical professionals, and business leaders.
For those interested in tracking developments, reliable sources include the National Conference of State Legislatures’ cannabis legislation database, the Congressional Research Service’s reports on federal cannabis policy, and peer-reviewed studies published in journals like JAMA and the American Journal of Public Health. State health departments and revenue agencies also provide regular updates on licensing, tax collections, and public health metrics related to cannabis programs.
The conversation around cannabis legalization continues to evolve, reflecting changing social norms, scientific understanding, and political realities. While the path forward remains uncertain, the enduring public support for reform suggests that the debate over how best to regulate cannabis will remain a significant feature of American policy discourse for years to come.